Sansure Biotech Inc. Stock

Equities

688289

CNE1000043J1

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. 06:00:00 2024-04-21 pm EDT 5-day change 1st Jan Change
18.33 CNY -0.33% Intraday chart for Sansure Biotech Inc. -1.35% -6.24%
Sales 2024 * - Sales 2025 * - Capitalization 10.49B 75.96B
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
43.6 x
P/E ratio 2025 *
28.2 x
Employees 2,567
Yield 2024 *
-
Yield 2025 *
-
Free-Float 46.34%
More Fundamentals * Assessed data
Dynamic Chart
Sansure Biotech's 2023 Profit Drops 81% as Revenue Slumps 84% MT
Sansure Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ASEP Medical Holdings Signs JV Agreement with Chinese Medical Diagnostics Co Sansure Biotech Inc. MT
Sansure Biotech Secures EU Certification For In Vitro Diagnostic Device MT
Sansure Biotech Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tranche Update on Sansure Biotech Inc.'s Equity Buyback Plan announced on October 21, 2022. CI
Sansure Biotech Inc.'s Equity Buyback announced on October 21, 2022, has closed with 9,865,793 shares, representing 1.7% for CNY 200 million. CI
Sansure Biotech Gets EU CE certification for 60 products MT
Certain A Shares of Sansure Biotech Inc. are subject to a Lock-Up Agreement Ending on 28-AUG-2023. CI
Sansure Biotech Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Sansure Biotech's Human Papillomavirus Kit Gets EU Registration Certificate MT
Tranche Update on Sansure Biotech Inc.'s Equity Buyback Plan announced on October 21, 2022. CI
Sansure Biotech Inc.(SHSE:688289) dropped from Shanghai Stock Exchange Health Care Sector Index CI
Sansure Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Tranche Update on Sansure Biotech Inc.'s Equity Buyback Plan announced on October 21, 2022. CI
More news
1 day-0.33%
1 week-1.35%
Current month-5.03%
1 month-11.45%
3 months+3.97%
6 months+19.03%
Current year-6.24%
More quotes
1 week
17.93
Extreme 17.93
18.62
1 month
17.93
Extreme 17.93
20.85
Current year
16.08
Extreme 16.08
22.00
1 year
14.72
Extreme 14.72
23.35
3 years
14.72
Extreme 14.72
75.44
5 years
14.72
Extreme 14.72
105.10
10 years
14.72
Extreme 14.72
105.10
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 08-04-22
Chairman 40 09-12-31
Director of Finance/CFO 48 17-07-31
Members of the board TitleAgeSince
Director/Board Member 60 16-06-30
Chief Executive Officer 56 08-04-22
Director/Board Member 45 08-11-30
More insiders
Date Price Change Volume
24-04-22 18.33 -0.33% 3,164,371
24-04-19 18.39 +0.33% 2,524,284
24-04-18 18.33 +0.44% 4,066,461
24-04-17 18.25 +0.33% 5,440,224
24-04-16 18.19 -2.10% 6,076,596

End-of-day quote Shanghai S.E., April 21, 2024

More quotes
Sansure Biotech Inc is a company mainly engaged in research and development, production and sales of diagnostic reagents and instruments. The Company's diagnostic reagent products are comprised of viral hepatitis series, reproductive tract infection and genetic series, pediatric infection series and nucleic acid blood screening series. The instrument products include automatic nucleic acid detection reaction system construction series and fluorescent polymerase chain reaction (PCR) monitoring and analysis software. The Company also provides related inspection services, including medical inspection and scientific research services which are provided for medical institutions.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688289 Stock